Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457. | Br J Haematol;156(2): 265-8, 2012 Jan. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457.

Mancini, Manuela; Aluigi, Michela; Leo, Elisa; Marcozzi, Chiara; Castagnetti, Fausto; Barbieri, Enza; Santucci, Maria Alessandra.

Br J Haematol ; 156(2): 265-8, 2012 Jan.

Article in En | MEDLINE | ID: mdl-22103975

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Histones / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Protein Serine-Threonine Kinases Type of study: Diagnostic_studies Limits: Animals / Humans Language: En Journal: Br J Haematol Year: 2012 Document type: Article Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Histones / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Protein Serine-Threonine Kinases Type of study: Diagnostic_studies Limits: Animals / Humans Language: En Journal: Br J Haematol Year: 2012 Document type: Article Country of publication: